A 52-Week, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects with Parkinson's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date5/1/19 → 6/14/21

Funding

  • AbbVie Incorporated: $54,101.00